loading page

Serum C-Reactive Protein Greater than 75 mg/dl as an Early Available Laboratory Predictor of Severe COVID-19: A Systematic Review
  • +3
  • Pershang Nazemi,
  • SeyedAhmad SeyedAlinaghi,
  • Ayein Azarnoush,
  • Avin Mabadi,
  • Arezoo Salami khaneshan,
  • Mohammadreza Salehi
Pershang Nazemi
Tehran University of Medical Sciences
Author Profile
SeyedAhmad SeyedAlinaghi
Tehran University of Medical Sciences
Author Profile
Ayein Azarnoush
Alborz University of Medical Sciences

Corresponding Author:[email protected]

Author Profile
Avin Mabadi
Iran University of Medical Sciences
Author Profile
Arezoo Salami khaneshan
Tehran University of Medical Sciences
Author Profile
Mohammadreza Salehi
Tehran University of Medical Sciences
Author Profile

Abstract

Abstract Introduction Severe COVID-19 management is still challenging. Having a laboratory factor to predict the severity of a patient’s condition can be very useful in how to approach each patient. There have been studies concentrating on the correlation between serum C-reactive protein (CRP) level and COVID-19 severity but we aim to reach a threshold for CRP in disease severity determination. Methods We conducted a thorough search on PubMed, Web of Science and Google Scholar databases, and 323 studies were assessed for eligibility in three phases. The T-test was applied for the CRP level cutoffs. Results Eventually, 11 articles and 1615 patients were included in this systematic review. Our analysis evaluated combined mean, median, and standard deviation of severe patients’ CRP to be respectively 73.37, 53.80 and 47.936. Based on the combined mean, 75mg/dl was suggested as an initial threshold for baseline CRP in hospitalized patients for developing severe conditions. Conclusion This study recommends that COVID-19 patients with on-admission serum CRP levels of 75 mg/dl and more are likely associated with severe conditions. Thus, anti-inflammatory agents and further following may be helpful in these patients.
21 Nov 2022Submitted to Immunity, Inflammation and Disease
15 Feb 2023Submission Checks Completed
15 Feb 2023Assigned to Editor
20 Feb 2023Review(s) Completed, Editorial Evaluation Pending
23 Feb 2023Reviewer(s) Assigned
09 Mar 2023Editorial Decision: Revise Major
31 May 20231st Revision Received
11 Sep 2023Submission Checks Completed
11 Sep 2023Assigned to Editor
11 Sep 2023Review(s) Completed, Editorial Evaluation Pending
11 Sep 2023Reviewer(s) Assigned
03 Oct 2023Editorial Decision: Revise Major